At a glance
- Originator Novartis
- Class Antineoplastics; Phospholipids; Piperidines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 15 Jul 1998 Profile reviewed
- 15 Jul 1998 No-Development-Reported for Cancer in Germany (Unknown route)
- 15 Jul 1998 No-Development-Reported for Cancer in USA (Unknown route)